A Review on Biosimilar Infliximab, CT-P13, in the Treatment of Inflammatory Bowel Disease [PDF]
Immunotherapy, 2017 The introduction of biological agents has led to significant changes in the treatment of inflammatory bowel disease (IBD). The relatively high price of infliximab (IFX) and the expiration of the patents led to the introduction of biosimilar agents. CT-P13 was the first IFX biosimilar approved in the same indications as the reference product; however ...
Farkas Klaudia, Molnár Tamás
openaire +3 more sources
Biosimilar infliximab introduction into the gastro-enterology care pathway in a large acute Irish teaching hospital: a story behind the evidence [PDF]
, 2018 Background and aim: Biosimilar medicines are not considered exact replicas of originator biological medicines. As a result, prescribers can be hesitant to introduce such medicines into the clinical setting until evidence surfaces confirming their safety ...
Byrne, Stephen +5 more
core +1 more source
Frontiers in Pharmacology, 2021 Background: Crohn disease (CD) is a chronic inflammatory disease that affects quality of life. There are several drugs available for the treatment of CD, but their relative efficacy is unknown due to a lack of high-quality head-to-head randomized ...
Guozhi Wu +11 more
doaj +1 more source
Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up [PDF]
Anais Brasileiros de Dermatologia, 2019 Patricia Shu Kurizky +2 more
doaj +2 more sources
Tumor necrosis factor inhibitors in psoriatic arthritis. [PDF]
, 2017 INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory disease that can result in significant disability. With the emergence of tumor necrosis factor inhibitors (TNFi), therapeutic outcomes in PsA have improved substantially.
Kraft, Walter K. +2 more
core +2 more sources
Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort [PDF]
, 2023 BACKGROUND: Switching from originator infliximab (IFX) to biosimilar IFX is effective and safe. However, data on multiple switching are scarce. The Edinburgh inflammatory bowel disease (IBD) unit has undertaken three switch programmes: (1) Remicade to CT-
Arnott, Ian D +9 more
core +1 more source
The Role of Infliximab Biosimilar CT-P13 in Inflammatory Bowel Disease [PDF]
Journal of Exploratory Research in Pharmacology, 2017 The advent of targeted biologic therapies for debilitating disorders such as Crohn’s disease (CD) and Ulcerative Colitis (UC) has changed management and significantly improved outcomes. However, biologic agents are expensive, and the introduction of biosimilar medications for the treatment of inflammatory bowel diseases presents a lower-cost ...
Devika Kapuria, Rajiv Chhabra
openaire +1 more source
Long term efficacy, safety and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort [PDF]
, 2018 K
Banai, János +25 more
core +1 more source
Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease. [PDF]
Dig Dis Sci, 2020 Biosimilar approval, such as Inflectra™ (CT-P13) for treating ulcerative colitis (UC) and Crohn's disease (CD), has reduced direct drug costs. Though clinicians are comfortable with biosimilar use in treatment-naïve patients, there are concerns in some jurisdictions that there are insufficient data from well-controlled trials to support non-medical ...
Bernard EJ, Fedorak RN, Jairath V.
europepmc +4 more sources
Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland [PDF]
, 2017 Increasing numbers of biosimilar medicines are becoming available. The objective of this survey was to assess awareness of and attitudes to biosimilars amongst physicians (medical specialists and General Practitioners (GPs)) and community pharmacists in ...
Bermingham, Margaret +6 more
core +1 more source